Following the visit of Dr. Giancarlo Francese, Senior Program Officer from the Bill & Melinda Gates Foundation (the foundation), to our site in Morocco, MARBIO is delighted to announce new grant funding from the foundation. MARBIO, with support from the foundation, aims to develop a new self-injectable contraceptive formulation, for women and girls in low- and middle-income countries. The goal is to expand and facilitate access to modern contraceptive options, thereby improving women's reproductive health, reducing poverty, and promoting gender equality, positively transforming the lives of millions of women and girls across Africa and other Low Middle Income Countries (LMICs).
Recipharm’s new CEO on ‘fast and furious’ changes, with eyes on GLP-1, biologics manufacturing
Another sign that the post-pandemic reshaping of the CDMO industry isn't over came Tuesday as one of the sector’s most powerful companies, Recipharm, sold off seven of its manufacturing and development facilities in Europe to Blue Wolf Capital.
HOLMES CHAPEL, UK / ACCESSWIRE / April 2, 2024 / Bespak today announced the completion of the transaction to separate Recipharm's former Advanced Delivery Systems Business Unit from the Recipharm Group to form a new standalone company. Both Bespak and Recipharm are backed by EQT Private Equity. The spin-out has created a leading global contract development and manufacturing organisation (CDMO) focused on drug-device combination products and drug delivery devices for pulmonary and nasal inhalation.
Blue Wolf Capital to Acquire OSD CDMO Sites from Recipharm
Recipharm, a global leader in contract development and manufacturing, has announced two major milestones as part of its ongoing commitment to sustainability, underpinning the Group’s pledge to minimising its environmental impact.
ReciBioPharm, the advanced and emerging therapies business unit of Recipharm, has announced a collaboration agreement with GeneVentiv Therapeutics, a pre-clinical gene therapy company, to advance development of an Adeno-Associated Virus (AAV)-based universal gene therapy for haemophilia, and the first to treat haemophilia patients with inhibitors.
Recipharm, Medspray, and Resyca enter into exclusive license agreement to develop nasally-delivered drug products using proprietary soft mist technology
Recipharm harmonizes its global quality operations with Veeva Vault Quality
ReciBioPharm partners with Acuitas Therapeutics to provide rapid technology transfers and CGMP manufacture of Acuitas` LNP formulations